On June 22, 2026, China’s Ministry of Commerce (MOFCOM), National Development and Reform Commission (NDRC), and Ministry of Finance jointly issued the 2026 Action Plan for Stabilizing and Improving Foreign Investment Utilization — a 15-point plan spanning market access, investment facilitation, promotion, service guarantees, and regulatory optimization. It arrives at a moment when China’s actual FDI utilization dropped 27% year-on-year in the first five months of 2026.
Why It Matters
This is not a routine policy document. Previous rounds of “opening up” focused on headline market access — qualified investor schemes, bond market entry, ownership caps. The 2026 Action Plan reads differently: it targets the operational bottlenecks that foreign-invested enterprises (FIEs) have been raising for years. Cross-border financing friction, derivatives access, M&A review timelines, data export rules. These are the problems that make running a China subsidiary expensive and slow, not the problems that make headlines.
Five of the 15 measures carry the most immediate weight. Below, we break down what each means and what your company should do about it — now, before the formal implementing rules drop.
The Details
1. Financial sector access moves from headline to operational. The plan commits to letting foreign institutions use treasury bond futures and other risk management tools. It also introduces cross-border financing facilitation quotas for “key FIEs” and “proxy documentation” international settlement through domestic banks. For the first time, regulators are targeting the day-to-day treasury friction — cash pooling, hedging, intercompany lending — that large foreign enterprises actually face, not just qualified investor scheme access.
2. Pharma and biotech get a faster pathway. The plan promises accelerated market access for innovative drugs and medical devices already approved in major foreign jurisdictions. This addresses a long-standing complaint: drugs that take 12-18 months for China National Medical Products Administration (NMPA) approval after EMA or FDA clearance. Implementation details are pending, but the direction is clear — shortened review timelines for products with existing regulatory approvals in recognized markets. For foreign pharma companies, this could cut China launch timelines by 6-9 months.
3. M&A rules are being rewritten. The plan calls for revised cross-border merger and acquisition procedures, including streamlined antitrust review for transactions below certain thresholds. For foreign companies looking to acquire Chinese assets or restructure existing joint ventures, this could cut deal timelines by 2-4 months. The NDRC is expected to publish draft revised rules in Q3 2026.
4. Cross-border data transfer gets a negative-list model. Building on the Tianjin Free Trade Zone (FTZ) pilot — China’s first negative list for cross-border data transfer released in July 2026 — the plan commits to expanding this approach nationally. Instead of the current security-assessment-first model where every data export needs pre-approval, the negative list specifies what cannot be exported; everything else flows freely. This is the single biggest friction-removal measure for companies in manufacturing, professional services, and technology.
5. Reinvestment incentives get real teeth. Foreign companies that reinvest China-generated profits domestically will qualify for temporary exemption from withholding tax. Combined with the existing policy of deferred tax payment on reinvestment, this creates a meaningful incentive to keep capital in China rather than repatriating. MOFCOM estimates this could retain an additional RMB 50-80 billion in reinvested earnings annually across the FIE base.
What You Should Do
- Raise cross-border financing quotas now. If your China entity has material treasury operations, start discussions with your relationship banks. Implementation of the “key FIE” quota system will likely favor early movers who have already documented their financing needs.
- Audit your data flows. Map which categories of data your China operations export and compare them against the Tianjin FTZ negative list as a preview of what the national model will look like. This positions you to move fast when the national list drops — expected by Q4 2026.
- Review your M&A pipeline. If you have a pending or planned China acquisition, flag it with your legal team to watch for the revised NDRC rules. The streamlined antitrust review could meaningfully change deal economics, especially for mid-market transactions.
- Model the reinvestment incentive. Run the numbers on whether deferring profit repatriation in favor of domestic reinvestment pencils out. For companies in manufacturing and R&D, the combined tax benefit can reach 10-15% of the reinvested amount, making expansion versus repatriation a genuinely different financial decision.
One Data Point
The number to remember: 27%. That is the year-on-year decline in China’s actual FDI utilization from January to May 2026 — the steepest FDI contraction in over a decade. The 2026 Action Plan is not a routine policy update. Every one of its 15 measures is designed to reverse this number. For foreign companies that act on the early-mover opportunities embedded in the plan, this is a window where policy momentum is unusually aligned with business interests.
Where to Go From Here
For the data-transfer dimension of this plan, read our analysis of the Shanghai and Tianjin FTZ cross-border data pilots — the models that the national negative list will be built on.
If you are evaluating market-entry structures, our guide on WFOE vs Joint Venture vs Representative Office walks through which entity type gives you the most operational flexibility under the new rules.
— China Gateway 360 —
Remote China market entry support, built around execution.
